BR112012009250A2 - composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma - Google Patents

composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma

Info

Publication number
BR112012009250A2
BR112012009250A2 BR112012009250A BR112012009250A BR112012009250A2 BR 112012009250 A2 BR112012009250 A2 BR 112012009250A2 BR 112012009250 A BR112012009250 A BR 112012009250A BR 112012009250 A BR112012009250 A BR 112012009250A BR 112012009250 A2 BR112012009250 A2 BR 112012009250A2
Authority
BR
Brazil
Prior art keywords
day
weeks
amount
treatment
composition
Prior art date
Application number
BR112012009250A
Other languages
English (en)
Inventor
Qin Albert
J Oleary James
Elizabeth Sarah Schindler Joanne
Lambert John
Weitman Steven
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of BR112012009250A2 publication Critical patent/BR112012009250A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

regime de aplicação de dose e método de tratamento. esta invenção refere-se a um método de tratamento e regime de aplicação de dose para o tratamento de doença, tal como câncer e tumores em mamíferos, em que a terapia com um fármaco citotóxico é adequada, pela administração de um conjugado de anticorpo-toxina, tal como uma toxina maitansinoide, por infusão a uma taxa de infusão inicial de 1 mg/min, ou mais baixa, em uma programação selecionada do grupo consistindo em: (1) uma quantidade de pelo menos cerca de 90 0g/m^ 2^ no dia 1 e dia 8, a cada três semanas, (2) pelo menos uma quantidade de cerca de 30 mg/m^ 2^ no dia 1, dia 2 e dia 3, a cada três semanas, (3) pelo menos uma quantidade de cerca de 45 mg/m^ 2^ no dia 1, dia 8, e dia 15, a cada 4 semanas; e (4) pelo menos uma quantidade de cerca de 45 mg/m^ 2^ no dia 1, dia 8 e dia 15, a cada 3 semanas.
BR112012009250A 2009-10-21 2010-10-21 composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma BR112012009250A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25380409P 2009-10-21 2009-10-21
PCT/US2010/053579 WO2011050180A1 (en) 2009-10-21 2010-10-21 Novel dosing regimen and method of treatment

Publications (1)

Publication Number Publication Date
BR112012009250A2 true BR112012009250A2 (pt) 2017-06-20

Family

ID=43898626

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009250A BR112012009250A2 (pt) 2009-10-21 2010-10-21 composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma

Country Status (13)

Country Link
US (1) US20110097345A1 (pt)
EP (1) EP2490715A4 (pt)
JP (1) JP2013508400A (pt)
KR (1) KR20120094472A (pt)
CN (1) CN102630165A (pt)
AU (1) AU2010310577A1 (pt)
BR (1) BR112012009250A2 (pt)
CA (1) CA2775806A1 (pt)
IL (1) IL219279A0 (pt)
IN (1) IN2012DN02826A (pt)
MX (1) MX2012004406A (pt)
RU (1) RU2012120691A (pt)
WO (1) WO2011050180A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2011091286A1 (en) * 2010-01-21 2011-07-28 Immunogen, Inc. Compositions and methods for treatment of ovarian cancer
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014052876A1 (en) * 2012-09-28 2014-04-03 Immunogen Inc. Methods for increasing efficacy of cd56- based therapy
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
RU2015149285A (ru) * 2013-05-14 2017-06-19 Иммьюноджен Инк. Схемы дозирования иммуноконъюгата anti-folr1
KR20220136468A (ko) * 2013-10-08 2022-10-07 이뮤노젠 아이엔씨 항-folr1 면역접합체 투여 레지멘
EP3553087A1 (en) * 2014-01-08 2019-10-16 The Board of Trustees of the Leland Stanford Junior University Targeted therapy for lung cancer
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
MX2019001608A (es) * 2016-08-10 2019-08-29 Celgene Corp Tratamiento de tumores y linfomas no de hodgkin solidos, reincididos y/o refractarios.
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3814378A1 (en) * 2018-06-26 2021-05-05 ImmunoGen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
AU2021286202A1 (en) * 2020-06-04 2023-01-19 Bioinvent International Ab Improving antibody tolerability associated with intravenous administration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1229934B1 (en) * 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) * 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1427377A4 (en) * 2001-09-20 2006-04-12 Cornell Res Foundation Inc METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISEASES USING BINDERS SPECIFIC TO THE PROSTATE-SPECIFIC MEMBRANEANT
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004110498A2 (en) * 2003-05-14 2004-12-23 Immunogen, Inc. Drug conjugate composition
CA2525987A1 (en) * 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
NZ576122A (en) * 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US8563700B2 (en) * 2008-06-16 2013-10-22 Immunogen, Inc. Synergistic effects
WO2011091286A1 (en) * 2010-01-21 2011-07-28 Immunogen, Inc. Compositions and methods for treatment of ovarian cancer
AU2012240448A1 (en) * 2011-04-01 2013-03-28 Immunogen, Inc. Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer

Also Published As

Publication number Publication date
AU2010310577A1 (en) 2012-04-19
KR20120094472A (ko) 2012-08-24
WO2011050180A1 (en) 2011-04-28
EP2490715A1 (en) 2012-08-29
IN2012DN02826A (pt) 2015-07-24
RU2012120691A (ru) 2013-11-27
CA2775806A1 (en) 2011-04-28
JP2013508400A (ja) 2013-03-07
US20110097345A1 (en) 2011-04-28
IL219279A0 (en) 2012-06-28
EP2490715A4 (en) 2013-06-26
MX2012004406A (es) 2012-05-08
CN102630165A (zh) 2012-08-08

Similar Documents

Publication Publication Date Title
BR112012009250A2 (pt) composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
MX2009004803A (es) Nanoparticulas de paclitaxel y albumina en combinacion con bevacizumab contra el cancer.
NZ588913A (en) Liver cancer drug
Teicher et al. The promise of antibody-drug conjugates
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
MY166014A (en) Combination therapy methods for treating proliferative diseases
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
BR112013031033A2 (pt) composição destinada ao tratamento de diabetes, compreendendo conjugado de insulina de ação prolongada e conjugado de peptídeo insulinotrópico de ação prolongada
EA201070757A1 (ru) Режим дозирования инъекционных препаратов эфиров палиперидона длительного действия
IN2015DN03219A (pt)
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
RU2012147340A (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
MY194576A (en) Methods for the treatment of recurrent glioblastoma (rgbm)
MX2016001541A (es) Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos.
SG194735A1 (en) Compositions and methods for treating cancer
CL2008001332A1 (es) Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]